Logo image of ABBV

ABBVIE INC (ABBV) Stock Overview

NYSE:ABBV - US00287Y1091 - Common Stock

210.6 USD
+1.1 (+0.53%)
Last: 8/22/2025, 8:04:00 PM
210.6 USD
0 (0%)
Pre-Market: 8/25/2025, 4:00:59 AM

ABBV Key Statistics, Chart & Performance

Key Statistics
52 Week High218.66
52 Week Low163.81
Market Cap372.04B
Shares1.77B
Float1.76B
Yearly Dividend6.24
Dividend Yield3.13%
EPS(TTM)10.59
PE19.89
Fwd PE14.51
Earnings (Next)10-28 2025-10-28/bmo
IPO01-02 2013-01-02
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ABBV short term performance overview.The bars show the price performance of ABBV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10

ABBV long term performance overview.The bars show the price performance of ABBV in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40 50

The current stock price of ABBV is 210.6 USD. In the past month the price increased by 10.68%. In the past year, price increased by 6.61%.

ABBVIE INC / ABBV Daily stock chart

ABBV Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
AMGN AMGEN INC 13.47 158.13B
GILD GILEAD SCIENCES INC 14.83 142.41B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 62.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.56B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 6.35 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.7 20.42B
SMMT SUMMIT THERAPEUTICS INC N/A 19.46B

About ABBV

Company Profile

ABBV logo image AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Company Info

ABBVIE INC

1 N Waukegan Rd

North Chicago ILLINOIS 60064 US

CEO: Richard A. Gonzalez

Employees: 55000

ABBV Company Website

ABBV Investor Relations

Phone: 18479327900

ABBVIE INC / ABBV FAQ

What is the stock price of ABBVIE INC today?

The current stock price of ABBV is 210.6 USD. The price increased by 0.53% in the last trading session.


What is the ticker symbol for ABBVIE INC stock?

The exchange symbol of ABBVIE INC is ABBV and it is listed on the New York Stock Exchange, Inc. exchange.


On which exchange is ABBV stock listed?

ABBV stock is listed on the New York Stock Exchange, Inc. exchange.


What is the price forecast or stock price prediction for ABBVIE INC stock?

34 analysts have analysed ABBV and the average price target is 221.28 USD. This implies a price increase of 5.07% is expected in the next year compared to the current price of 210.6. Check the ABBVIE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABBVIE INC worth?

ABBVIE INC (ABBV) has a market capitalization of 372.04B USD. This makes ABBV a Mega Cap stock.


How many employees does ABBVIE INC have?

ABBVIE INC (ABBV) currently has 55000 employees.


What are the support and resistance levels for ABBVIE INC (ABBV) stock?

ABBVIE INC (ABBV) has a support level at 195.63. Check the full technical report for a detailed analysis of ABBV support and resistance levels.


Is ABBVIE INC (ABBV) expected to grow?

The Revenue of ABBVIE INC (ABBV) is expected to grow by 8.23% in the next year. Check the estimates tab for more information on the ABBV EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABBVIE INC (ABBV) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABBVIE INC (ABBV) stock pay dividends?

ABBVIE INC (ABBV) has a dividend yield of 3.13%. The yearly dividend amount is currently 6.24. Check the full fundamental report for a detailed analysis of ABBV dividend history, reliability and sustainability.


When does ABBVIE INC (ABBV) report earnings?

ABBVIE INC (ABBV) will report earnings on 2025-10-28, before the market open.


What is the Price/Earnings (PE) ratio of ABBVIE INC (ABBV)?

The PE ratio for ABBVIE INC (ABBV) is 19.89. This is based on the reported non-GAAP earnings per share of 10.59 and the current share price of 210.6 USD. Check the full fundamental report for a full analysis of the valuation metrics for ABBV.


What is the Short Interest ratio of ABBVIE INC (ABBV) stock?

The outstanding short interest for ABBVIE INC (ABBV) is 0.86% of its float. Check the ownership tab for more information on the ABBV short interest.


ABBV Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ABBV. When comparing the yearly performance of all stocks, ABBV turns out to be only a medium performer in the overall market: it outperformed 65.34% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ABBV Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ABBV. While ABBV belongs to the best of the industry regarding profitability, there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABBV Financial Highlights

Over the last trailing twelve months ABBV reported a non-GAAP Earnings per Share(EPS) of 10.59. The EPS decreased by -1.03% compared to the year before.


Industry RankSector Rank
PM (TTM) 6.38%
ROA 2.71%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%12.08%
Sales Q2Q%6.65%
EPS 1Y (TTM)-1.03%
Revenue 1Y (TTM)6.05%

ABBV Forecast & Estimates

34 analysts have analysed ABBV and the average price target is 221.28 USD. This implies a price increase of 5.07% is expected in the next year compared to the current price of 210.6.

For the next year, analysts expect an EPS growth of 21.26% and a revenue growth 8.23% for ABBV


Analysts
Analysts78.82
Price Target221.28 (5.07%)
EPS Next Y21.26%
Revenue Next Year8.23%

ABBV Ownership

Ownership
Inst Owners74.78%
Ins Owners0.05%
Short Float %0.86%
Short Ratio2.63